Ine characteristics of individuals as outlined by antithrombotic approaches are presented in
Ine qualities of patients as outlined by antithrombotic strategies are presented in Table 1.J. Clin. Med. 2021, ten,4 ofTable 1. Baseline characteristics on the study group according to antithrombotic techniques.No OAC n = 308 Clinical Characteristic All n = 3614 OAC n = 3306 APT n = 135 74.6 (10.three) 18 (13.three) 46 (34.1) 71 (52.6) 60 (44.four) 80 (59.3) 14 (10.four) 41 (30.four) 112 (83.0) 92 (68.1) 112 (83.0) 107 (79.3) 60 (44.4) 32 (23.7) 25 (18.5) 53 (39.3) 14 (ten.four) four (3.0) 4 (3.0) 13 (9.6) 45 (33.3) 80 (59.three) 24 (17.eight) Heparin n = 96 72.6 (ten.two) 15 (15.9) 39 (40.six) 42 (43.8) 48 (50.0) 57 (59.4) 15 (15.6) 24 (25.0) 83 (86.5) 60 (62.five) 64 (66.7) 59 (61.five) 25 (26.0) 21 (21.9) 28 (29.two) 35 (36.five) 3 (3.1) 0 (0.0) two (2.1) 8 (eight.3) 25 (26.0) 40 (41.7) 11 (11.5) Without having any Stroke Prophylaxis n = 77 77.1 (12.1) ten (13.three) 24 (31.2) 43 (55.eight) 32 (41.six) 35 (45.5) 15 (19.five) 27 (35.1) 63 (81.8) 50 (64.9) 42 (54.five) 36 (46.8) 18 (23.four) 11 (14.3) 8 (10.four) 32 (41.6) four (5.two) two (two.six) 4 (5.two) five (six.5) 30 (39.0) 40 (51.9) 12 (15.6)Age imply (SD), years 65 6573.six (10.three) 598 (16.five) 1285 (35.6) 1731 (47.9) 1572 (43.five) 1723 (47.7) 803 (22.2) 1088 (30.1) 3174 (87.4) 2529 (70.0) 2207 (61.1) 1979 (54.8) 881 (24.4) 564 (15.6) 648 (17.9) 1341 (37.1) 118 (3.3) 29 (0.8) 149 (four.1) 186 (5.1) 872 (24.1) 1731 (47.9) 255 (6.two)73.5 (10.2) 555 (16.eight) 1188 (35.9) 1563 (47.3) 1445 (43.7) 1569 (47.five) 760 (23.0) 977 (29.six) 2918 (88.3) 2311 (69.9) 2005 (60.6) 1796 (54.three) 782 (23.7) 500 (15.1) 599 (18.1) 1218 (36.8) 93 (2.eight) 18 (0.five) 138 (4.2) 149 (4.5) 751 (22.7) 1555 (47.0) 178 (five.four)Female Paroxysmal Persistent Permanent Hypertension Heart failure Vascular disease Coronary artery illness Previous myocardial infarction Peripheral artery illness Previous stroke/TIA/systemic embolism Diabetes Dirlotapide Biological Activity mellitus Any prior bleeding Intracranial bleeding Gastrointestinal bleeding Cancer Hemoglobin 12 g/dL eGFR 60 mL/min/1.73 m2 eGFR 30 mL/min/1.73 CHA2 DS2 VASc score imply (SD) mType of atrial Isoprothiolane Autophagy fibrillationMedical historyThromboembolic danger 4.7 (1.6) 3331 (92.two) 1909 (52.eight) 4.7 (1.six) 3047 (92.two) 1737 (52.5) Bleeding threat HAS-BLED score mean (SD) 2.two (0.eight) 1208 (33.four) 13 (0.4) 796 (22.0) 372 (ten.3) 346 (9.six) 240 (6.six) 788 (21.eight) 189 (5.2) 191 (5.three) two.two (0.eight) 1078 (32.six) 11 (0.3) 784 (23.7) 338 (10.2) 329 (10.0) 197 (six.0) 714 (21.6) 172 (five.two) 180 (five.four) 2.three (0.9) 58 (43.0) 1 (0.7) 5 (three.7) 21 (15.six) five (three.7) 38 (28.1) 24 (17.eight) eight (five.9) 4 (three.0) two.21 (0.9) 33 (34.4) 0 (0.0) 21 (21.9) 7 (7.3) 11 (11.five) 7 (7.3) 16 (16.7) 7 (7.3) five (5.two) 2.2 (0.eight) 27 (35.1) 0 (0.0) four (five.two) five (six.5) five (6.5) 4 (5.two) 23 (29.9) 7 (9.1) three (3.9) 4.9 (1.6) 128 (94.eight) 80 (59.three) 4.9 (1.6) 90 (92.eight) 57 (59.4) four.5 (1.4) 72 (93.five) 39 (50.six)33Electrical cardioversion Planned coronarography/PCI CIED implantation/reimplantation Acute coronary syndrome Heart failure Ablation other than AF AF without the need of any proceduresReason for hospitalizationAbbreviations: AF, atrial fibrillation; APT, antiplatelet drug; CIED, cardiac implantable electronic device; eGFR, estimated glomerular filtration rate; IQR, interquartile variety; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; SD, common deviation; TIA, transient ischemic attack.J. Clin. Med. 2021, ten,5 of3.two. Antithrombotic Therapy Use Within the presented study, 3306 sufferers (91.five ) received OACs, 135 patients (three.7 ) received APT,96 (2.7 ) received heparin, and 77 (two.1 ) had been with out OACs or APT. Inside the group treated with OACs, 603 sufferers received VKA, and 2703 (82 ) were treated with.
